Metformin intake is associated with better survival in ovarian cancer: A case-control study

Cancer

Volumn 119, Issue 3, 2013, Pages 555-562

  Kumar, Sanjeev ^a   Meuter, Alexandra ^a   Thapa, Prabin ^a   Langstraat, Carrie ^a   Giri, Shailendra ^b   Chien, Jeremy ^b   Rattan, Ramandeep ^b   Cliby, William ^a   Shridhar, Viji ^b  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

Author keywords

drug repositioning; metformin; ovarian cancer; survival

Indexed keywords

ANTIDIABETIC AGENT; INSULIN; METFORMIN; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BODY MASS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIABETES MELLITUS; DISEASE SPECIFIC SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; OVARY CARCINOMA; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME;

AGED; ANTINEOPLASTIC AGENTS; CASE-CONTROL STUDIES; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVAL RATE;

EID: 84872978681     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27706     Document Type: Article

References (22)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Cannistra SA,. Cancer of the ovary. N Engl J Med. 1993; 329: 1550-1559.
3. Tobinick EL,. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect. 2009; 22: 119-125.
4. Campas C,. Drug repositioning summit: finding new routes to success. Drug News Perspect. 2009; 22: 126-128.
5. Richardson P,. Management of the relapsed/refractory myeloma patient: strategies incorporating lenalidomide. Semin Hematol. 2005; 42: S9-S15.
6. Rattan R, Giri S, Hartmann LC, Shridhar V,. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med. 2011; 15: 166-178.
7. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V,. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011; 13: 483-491.
8. Ben Sahra I, Laurent K, Loubat A, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27: 3576-3586.
9. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN,. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila). 2008; 1: 369-375.
10. Kisfalvi K, Eibl G, Sinnett-Smith J, Rozengurt E,. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009; 69: 6539-6545.
11. Isakovic A, Harhaji L, Stevanovic D, et al. Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis. Cell Mol Life Sci. 2007; 64: 1290-1302.
12. Romero IL, McCormick A, McEwen KA, et al. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012; 119: 61-67.
13. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005; 330: 1304-1305.
14. Bowker SL, Majumdar SR, Veugelers P, Johnson JA,. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29: 254-258.
15. Bakhru A, Buckanovich RJ, Griggs JJ,. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol. 2011; 121: 106-111.
16. Outwater EK, Wagner BJ, Mannion C, McLarney JK, Kim B,. Sex cord-stromal and steroid cell tumors of the ovary. Radiographics. 1998; 18: 1523-1546.
17. Efstathiou E, Dimopoulos MA, Bozas G, et al. Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res. 2007; 27: 611-617.
18. Aletti GD, Eisenhauer EL, Santillan A, et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment. Gynecol Oncol. 2011; 120: 23-28.
19. Apovian CM,. Management of diabetes across the course of disease: minimizing obesity-associated complications. Diabetes Metab Syndr Obes. 2011; 4: 353-369.
20. McTiernan A, Irwin M, Vongruenigen V,. Weight, physical activity, diet, and prognosis in breast and gynecologic cancers. J Clin Oncol. 2010; 28: 4074-4080.
21. Jiralerspong S, Palla SL, Giordano SH, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009; 27: 3297-3302.
22. Bower WF, Jin L, Underwood MJ, et al. Overt diabetes mellitus adversely affects surgical outcomes of noncardiovascular patients. Surgery. 2010; 147: 670-675.